nodes	percent_of_prediction	percent_of_DWPC	metapath
Clofarabine—Nucleic Acid Synthesis Inhibitors—Gemcitabine—urinary bladder cancer	0.205	0.515	CiPCiCtD
Clofarabine—Nucleic Acid Synthesis Inhibitors—Fluorouracil—urinary bladder cancer	0.193	0.485	CiPCiCtD
Clofarabine—RRM2—urinary bladder cancer	0.189	1	CbGaD
Clofarabine—RRM2—Gemcitabine—urinary bladder cancer	0.051	0.259	CbGbCtD
Clofarabine—RRM1—Gemcitabine—urinary bladder cancer	0.051	0.259	CbGbCtD
Clofarabine—Cytarabine—Gemcitabine—urinary bladder cancer	0.0459	0.35	CrCrCtD
Clofarabine—POLA1—Gemcitabine—urinary bladder cancer	0.0441	0.224	CbGbCtD
Clofarabine—Azacitidine—Gemcitabine—urinary bladder cancer	0.0436	0.333	CrCrCtD
Clofarabine—Decitabine—Gemcitabine—urinary bladder cancer	0.0415	0.317	CrCrCtD
Clofarabine—DCK—Gemcitabine—urinary bladder cancer	0.0271	0.138	CbGbCtD
Clofarabine—ABCG2—Fluorouracil—urinary bladder cancer	0.00495	0.0251	CbGbCtD
Clofarabine—ABCG2—Carboplatin—urinary bladder cancer	0.00492	0.025	CbGbCtD
Clofarabine—ABCG2—Cisplatin—urinary bladder cancer	0.0042	0.0213	CbGbCtD
Clofarabine—ABCG2—Etoposide—urinary bladder cancer	0.00413	0.021	CbGbCtD
Clofarabine—ABCG2—Doxorubicin—urinary bladder cancer	0.00282	0.0143	CbGbCtD
Clofarabine—ABCG2—Methotrexate—urinary bladder cancer	0.00273	0.0138	CbGbCtD
Clofarabine—POLA1—prostate gland—urinary bladder cancer	0.000897	0.0717	CbGeAlD
Clofarabine—RRM2—prostate gland—urinary bladder cancer	0.000857	0.0685	CbGeAlD
Clofarabine—POLA1—seminal vesicle—urinary bladder cancer	0.000759	0.0607	CbGeAlD
Clofarabine—RRM1—prostate gland—urinary bladder cancer	0.000712	0.0569	CbGeAlD
Clofarabine—Cytarabine—POLB—urinary bladder cancer	0.000691	0.635	CrCbGaD
Clofarabine—RRM1—seminal vesicle—urinary bladder cancer	0.000602	0.0481	CbGeAlD
Clofarabine—POLA1—urethra—urinary bladder cancer	0.000601	0.048	CbGeAlD
Clofarabine—RRM2—renal system—urinary bladder cancer	0.000584	0.0467	CbGeAlD
Clofarabine—DCK—prostate gland—urinary bladder cancer	0.000553	0.0442	CbGeAlD
Clofarabine—RRM1—smooth muscle tissue—urinary bladder cancer	0.000504	0.0403	CbGeAlD
Clofarabine—RRM1—renal system—urinary bladder cancer	0.000485	0.0388	CbGeAlD
Clofarabine—RRM1—urethra—urinary bladder cancer	0.000477	0.0381	CbGeAlD
Clofarabine—RRM2—female reproductive system—urinary bladder cancer	0.000468	0.0374	CbGeAlD
Clofarabine—DCK—seminal vesicle—urinary bladder cancer	0.000468	0.0374	CbGeAlD
Clofarabine—POLA1—vagina—urinary bladder cancer	0.000443	0.0354	CbGeAlD
Clofarabine—RRM2—vagina—urinary bladder cancer	0.000423	0.0338	CbGeAlD
Clofarabine—RRM1—female reproductive system—urinary bladder cancer	0.000389	0.0311	CbGeAlD
Clofarabine—DCK—urethra—urinary bladder cancer	0.00037	0.0296	CbGeAlD
Clofarabine—RRM1—vagina—urinary bladder cancer	0.000352	0.0281	CbGeAlD
Clofarabine—ABCG2—prostate gland—urinary bladder cancer	0.000309	0.0247	CbGeAlD
Clofarabine—DCK—female reproductive system—urinary bladder cancer	0.000302	0.0241	CbGeAlD
Clofarabine—POLA1—lymph node—urinary bladder cancer	0.000286	0.0229	CbGeAlD
Clofarabine—RRM2—lymph node—urinary bladder cancer	0.000274	0.0219	CbGeAlD
Clofarabine—DCK—vagina—urinary bladder cancer	0.000273	0.0218	CbGeAlD
Clofarabine—ABCG2—seminal vesicle—urinary bladder cancer	0.000261	0.0209	CbGeAlD
Clofarabine—Cladribine—RRM2—urinary bladder cancer	0.000253	0.232	CrCbGaD
Clofarabine—DCK—Epirubicin—Valrubicin—urinary bladder cancer	0.000239	0.257	CbGdCrCtD
Clofarabine—DCK—Doxorubicin—Valrubicin—urinary bladder cancer	0.000239	0.257	CbGdCrCtD
Clofarabine—RRM1—lymph node—urinary bladder cancer	0.000227	0.0182	CbGeAlD
Clofarabine—ABCG2—urethra—urinary bladder cancer	0.000207	0.0165	CbGeAlD
Clofarabine—RRM1—Azacitidine—Gemcitabine—urinary bladder cancer	0.00018	0.194	CbGdCrCtD
Clofarabine—DCK—lymph node—urinary bladder cancer	0.000177	0.0141	CbGeAlD
Clofarabine—ABCG2—vagina—urinary bladder cancer	0.000152	0.0122	CbGeAlD
Clofarabine—Adenosine monophosphate—SRC—urinary bladder cancer	0.000145	0.133	CrCbGaD
Clofarabine—RRM2—Azacitidine—Gemcitabine—urinary bladder cancer	0.000113	0.122	CbGdCrCtD
Clofarabine—ABCG2—lymph node—urinary bladder cancer	9.85e-05	0.00788	CbGeAlD
Clofarabine—DCK—Doxorubicin—Epirubicin—urinary bladder cancer	8.3e-05	0.0893	CbGdCrCtD
Clofarabine—DCK—Epirubicin—Doxorubicin—urinary bladder cancer	7.68e-05	0.0826	CbGdCrCtD
Clofarabine—RRM2—Retinoblastoma (RB) in Cancer—CDKN1A—urinary bladder cancer	4.6e-05	0.00148	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle—STAG2—urinary bladder cancer	4.57e-05	0.00148	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle—LIG1—urinary bladder cancer	4.57e-05	0.00148	CbGpPWpGaD
Clofarabine—POLA1—Mitotic G1-G1/S phases—TYMS—urinary bladder cancer	4.55e-05	0.00147	CbGpPWpGaD
Clofarabine—RRM2—Mitotic G1-G1/S phases—RB1—urinary bladder cancer	4.51e-05	0.00145	CbGpPWpGaD
Clofarabine—DCK—Retinoblastoma (RB) in Cancer—CCND1—urinary bladder cancer	4.45e-05	0.00143	CbGpPWpGaD
Clofarabine—POLA1—E2F transcription factor network—CDKN2A—urinary bladder cancer	4.43e-05	0.00143	CbGpPWpGaD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	4.41e-05	0.00142	CbGpPWpGaD
Clofarabine—RRM2—E2F transcription factor network—MYC—urinary bladder cancer	4.39e-05	0.00142	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—GSTZ1—urinary bladder cancer	4.38e-05	0.00141	CbGpPWpGaD
Clofarabine—POLA1—Retinoblastoma (RB) in Cancer—RB1—urinary bladder cancer	4.38e-05	0.00141	CbGpPWpGaD
Clofarabine—DCK—Retinoblastoma (RB) in Cancer—CDKN1A—urinary bladder cancer	4.3e-05	0.00139	CbGpPWpGaD
Clofarabine—RRM1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	4.16e-05	0.00134	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—GSTO2—urinary bladder cancer	4.16e-05	0.00134	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—NAT1—urinary bladder cancer	4.16e-05	0.00134	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle—ESPL1—urinary bladder cancer	4.13e-05	0.00133	CbGpPWpGaD
Clofarabine—RRM1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	4.11e-05	0.00133	CbGpPWpGaD
Clofarabine—POLA1—Synthesis of DNA—RB1—urinary bladder cancer	4.05e-05	0.00131	CbGpPWpGaD
Clofarabine—RRM2—Mitotic G1-G1/S phases—CDKN2A—urinary bladder cancer	3.96e-05	0.00128	CbGpPWpGaD
Clofarabine—RRM2—G1/S Transition—CDKN1A—urinary bladder cancer	3.84e-05	0.00124	CbGpPWpGaD
Clofarabine—ABCG2—HIF-1-alpha transcription factor network—TERT—urinary bladder cancer	3.84e-05	0.00124	CbGpPWpGaD
Clofarabine—POLA1—S Phase—CDK4—urinary bladder cancer	3.82e-05	0.00123	CbGpPWpGaD
Clofarabine—RRM2—Retinoblastoma (RB) in Cancer—MYC—urinary bladder cancer	3.82e-05	0.00123	CbGpPWpGaD
Clofarabine—RRM1—Retinoblastoma (RB) in Cancer—TP53—urinary bladder cancer	3.81e-05	0.00123	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—UGT2B7—urinary bladder cancer	3.8e-05	0.00123	CbGpPWpGaD
Clofarabine—POLA1—DNA Replication—RB1—urinary bladder cancer	3.8e-05	0.00123	CbGpPWpGaD
Clofarabine—POLA1—G1/S Transition—RB1—urinary bladder cancer	3.66e-05	0.00118	CbGpPWpGaD
Clofarabine—POLA1—E2F transcription factor network—CDKN1A—urinary bladder cancer	3.62e-05	0.00117	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—GSTZ1—urinary bladder cancer	3.61e-05	0.00116	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle, Mitotic—SMC1A—urinary bladder cancer	3.58e-05	0.00116	CbGpPWpGaD
Clofarabine—DCK—Retinoblastoma (RB) in Cancer—MYC—urinary bladder cancer	3.57e-05	0.00115	CbGpPWpGaD
Clofarabine—POLA1—Mitotic G1-G1/S phases—CDK4—urinary bladder cancer	3.55e-05	0.00114	CbGpPWpGaD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	3.51e-05	0.00113	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle, Mitotic—STAG2—urinary bladder cancer	3.5e-05	0.00113	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle, Mitotic—LIG1—urinary bladder cancer	3.5e-05	0.00113	CbGpPWpGaD
Clofarabine—RRM1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	3.49e-05	0.00112	CbGpPWpGaD
Clofarabine—ABCG2—HIF-2-alpha transcription factor network—EP300—urinary bladder cancer	3.47e-05	0.00112	CbGpPWpGaD
Clofarabine—POLA1—E2F transcription factor network—EP300—urinary bladder cancer	3.45e-05	0.00111	CbGpPWpGaD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	3.45e-05	0.00111	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—NAT1—urinary bladder cancer	3.42e-05	0.0011	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—CYP4B1—urinary bladder cancer	3.42e-05	0.0011	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—GSTO2—urinary bladder cancer	3.42e-05	0.0011	CbGpPWpGaD
Clofarabine—RRM1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	3.41e-05	0.0011	CbGpPWpGaD
Clofarabine—DCK—Metabolism—GSTZ1—urinary bladder cancer	3.37e-05	0.00109	CbGpPWpGaD
Clofarabine—RRM2—Mitotic G1-G1/S phases—CCND1—urinary bladder cancer	3.35e-05	0.00108	CbGpPWpGaD
Clofarabine—POLA1—S Phase—RB1—urinary bladder cancer	3.32e-05	0.00107	CbGpPWpGaD
Clofarabine—POLA1—Mitotic M-M/G1 phases—SMC1A—urinary bladder cancer	3.28e-05	0.00106	CbGpPWpGaD
Clofarabine—POLA1—Retinoblastoma (RB) in Cancer—CCND1—urinary bladder cancer	3.25e-05	0.00105	CbGpPWpGaD
Clofarabine—RRM2—Mitotic G1-G1/S phases—CDKN1A—urinary bladder cancer	3.24e-05	0.00104	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—SLC19A1—urinary bladder cancer	3.23e-05	0.00104	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle—SMC1A—urinary bladder cancer	3.2e-05	0.00103	CbGpPWpGaD
Clofarabine—DCK—Metabolism—NAT1—urinary bladder cancer	3.2e-05	0.00103	CbGpPWpGaD
Clofarabine—DCK—Metabolism—GSTO2—urinary bladder cancer	3.2e-05	0.00103	CbGpPWpGaD
Clofarabine—RRM2—G1/S Transition—MYC—urinary bladder cancer	3.19e-05	0.00103	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—PRSS3—urinary bladder cancer	3.15e-05	0.00102	CbGpPWpGaD
Clofarabine—POLA1—Retinoblastoma (RB) in Cancer—CDKN1A—urinary bladder cancer	3.15e-05	0.00102	CbGpPWpGaD
Clofarabine—RRM2—Retinoblastoma (RB) in Cancer—TP53—urinary bladder cancer	3.13e-05	0.00101	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—UGT2B7—urinary bladder cancer	3.13e-05	0.00101	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle—STAG2—urinary bladder cancer	3.13e-05	0.00101	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle—LIG1—urinary bladder cancer	3.13e-05	0.00101	CbGpPWpGaD
Clofarabine—POLA1—Mitotic G1-G1/S phases—RB1—urinary bladder cancer	3.08e-05	0.000994	CbGpPWpGaD
Clofarabine—RRM1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	3.08e-05	0.000993	CbGpPWpGaD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	3.05e-05	0.000985	CbGpPWpGaD
Clofarabine—POLA1—E2F transcription factor network—MYC—urinary bladder cancer	3e-05	0.000969	CbGpPWpGaD
Clofarabine—ABCG2—HIF-1-alpha transcription factor network—CREBBP—urinary bladder cancer	3e-05	0.000967	CbGpPWpGaD
Clofarabine—RRM1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	2.98e-05	0.000961	CbGpPWpGaD
Clofarabine—RRM1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	2.97e-05	0.000959	CbGpPWpGaD
Clofarabine—DCK—Retinoblastoma (RB) in Cancer—TP53—urinary bladder cancer	2.93e-05	0.000944	CbGpPWpGaD
Clofarabine—DCK—Metabolism—UGT2B7—urinary bladder cancer	2.92e-05	0.000943	CbGpPWpGaD
Clofarabine—POLA1—Synthesis of DNA—CDKN1A—urinary bladder cancer	2.91e-05	0.000938	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle, Mitotic—RRM2—urinary bladder cancer	2.88e-05	0.000929	CbGpPWpGaD
Clofarabine—RRM1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	2.84e-05	0.000914	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—CYP4B1—urinary bladder cancer	2.82e-05	0.000909	CbGpPWpGaD
Clofarabine—RRM1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	2.76e-05	0.000889	CbGpPWpGaD
Clofarabine—ABCG2—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	2.73e-05	0.000881	CbGpPWpGaD
Clofarabine—POLA1—DNA Replication—CDKN1A—urinary bladder cancer	2.73e-05	0.00088	CbGpPWpGaD
Clofarabine—POLA1—Mitotic G1-G1/S phases—CDKN2A—urinary bladder cancer	2.71e-05	0.000874	CbGpPWpGaD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	2.7e-05	0.00087	CbGpPWpGaD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	2.69e-05	0.000866	CbGpPWpGaD
Clofarabine—RRM2—Mitotic G1-G1/S phases—MYC—urinary bladder cancer	2.69e-05	0.000866	CbGpPWpGaD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	2.68e-05	0.000863	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—SLC19A1—urinary bladder cancer	2.66e-05	0.000858	CbGpPWpGaD
Clofarabine—DCK—Metabolism—CYP4B1—urinary bladder cancer	2.63e-05	0.000849	CbGpPWpGaD
Clofarabine—POLA1—G1/S Transition—CDKN1A—urinary bladder cancer	2.63e-05	0.000848	CbGpPWpGaD
Clofarabine—POLA1—Retinoblastoma (RB) in Cancer—MYC—urinary bladder cancer	2.61e-05	0.000842	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—PRSS3—urinary bladder cancer	2.59e-05	0.000836	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle—RRM2—urinary bladder cancer	2.58e-05	0.000831	CbGpPWpGaD
Clofarabine—ABCG2—Fluoropyrimidine Activity—TP53—urinary bladder cancer	2.55e-05	0.000821	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—TYMP—urinary bladder cancer	2.52e-05	0.000812	CbGpPWpGaD
Clofarabine—DCK—Metabolism—SLC19A1—urinary bladder cancer	2.49e-05	0.000802	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle, Mitotic—CCNE1—urinary bladder cancer	2.48e-05	0.000801	CbGpPWpGaD
Clofarabine—RRM1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	2.47e-05	0.000797	CbGpPWpGaD
Clofarabine—POLA1—S Phase—CCND1—urinary bladder cancer	2.47e-05	0.000796	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle, Mitotic—SMC1A—urinary bladder cancer	2.45e-05	0.00079	CbGpPWpGaD
Clofarabine—Paraesthesia—Etoposide—urinary bladder cancer	2.44e-05	0.000605	CcSEcCtD
Clofarabine—RRM2—Cell Cycle, Mitotic—TYMS—urinary bladder cancer	2.44e-05	0.000786	CbGpPWpGaD
Clofarabine—Haematuria—Methotrexate—urinary bladder cancer	2.43e-05	0.000603	CcSEcCtD
Clofarabine—Pancreatitis—Doxorubicin—urinary bladder cancer	2.43e-05	0.000602	CcSEcCtD
Clofarabine—Weight decreased—Epirubicin—urinary bladder cancer	2.42e-05	0.0006	CcSEcCtD
Clofarabine—Dyspnoea—Etoposide—urinary bladder cancer	2.42e-05	0.0006	CcSEcCtD
Clofarabine—DCK—Metabolism—PRSS3—urinary bladder cancer	2.42e-05	0.000781	CbGpPWpGaD
Clofarabine—Somnolence—Etoposide—urinary bladder cancer	2.42e-05	0.000599	CcSEcCtD
Clofarabine—RRM1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	2.42e-05	0.000779	CbGpPWpGaD
Clofarabine—Hepatobiliary disease—Methotrexate—urinary bladder cancer	2.42e-05	0.000598	CcSEcCtD
Clofarabine—Epistaxis—Methotrexate—urinary bladder cancer	2.41e-05	0.000596	CcSEcCtD
Clofarabine—Vomiting—Thiotepa—urinary bladder cancer	2.41e-05	0.000596	CcSEcCtD
Clofarabine—Pneumonia—Epirubicin—urinary bladder cancer	2.4e-05	0.000595	CcSEcCtD
Clofarabine—Infestation—Epirubicin—urinary bladder cancer	2.39e-05	0.000592	CcSEcCtD
Clofarabine—Infestation NOS—Epirubicin—urinary bladder cancer	2.39e-05	0.000592	CcSEcCtD
Clofarabine—Rash—Thiotepa—urinary bladder cancer	2.39e-05	0.000591	CcSEcCtD
Clofarabine—POLA1—S Phase—CDKN1A—urinary bladder cancer	2.39e-05	0.00077	CbGpPWpGaD
Clofarabine—Dermatitis—Thiotepa—urinary bladder cancer	2.38e-05	0.00059	CcSEcCtD
Clofarabine—Headache—Thiotepa—urinary bladder cancer	2.37e-05	0.000587	CcSEcCtD
Clofarabine—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	2.37e-05	0.000587	CcSEcCtD
Clofarabine—Decreased appetite—Etoposide—urinary bladder cancer	2.36e-05	0.000585	CcSEcCtD
Clofarabine—Pancytopenia—Doxorubicin—urinary bladder cancer	2.36e-05	0.000583	CcSEcCtD
Clofarabine—Renal failure—Epirubicin—urinary bladder cancer	2.35e-05	0.000582	CcSEcCtD
Clofarabine—Gastrointestinal disorder—Etoposide—urinary bladder cancer	2.35e-05	0.000581	CcSEcCtD
Clofarabine—Body temperature increased—Cisplatin—urinary bladder cancer	2.35e-05	0.000581	CcSEcCtD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	2.34e-05	0.000756	CbGpPWpGaD
Clofarabine—Fatigue—Etoposide—urinary bladder cancer	2.34e-05	0.00058	CcSEcCtD
Clofarabine—Neuropathy peripheral—Epirubicin—urinary bladder cancer	2.34e-05	0.00058	CcSEcCtD
Clofarabine—Jaundice—Epirubicin—urinary bladder cancer	2.33e-05	0.000577	CcSEcCtD
Clofarabine—Stomatitis—Epirubicin—urinary bladder cancer	2.33e-05	0.000577	CcSEcCtD
Clofarabine—Pain—Etoposide—urinary bladder cancer	2.33e-05	0.000576	CcSEcCtD
Clofarabine—Neutropenia—Doxorubicin—urinary bladder cancer	2.32e-05	0.000574	CcSEcCtD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	2.32e-05	0.000747	CbGpPWpGaD
Clofarabine—Hypersensitivity—Fluorouracil—urinary bladder cancer	2.31e-05	0.000571	CcSEcCtD
Clofarabine—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	2.3e-05	0.000571	CcSEcCtD
Clofarabine—Haemoglobin—Methotrexate—urinary bladder cancer	2.3e-05	0.000571	CcSEcCtD
Clofarabine—RRM1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	2.3e-05	0.000742	CbGpPWpGaD
Clofarabine—Haemorrhage—Methotrexate—urinary bladder cancer	2.29e-05	0.000568	CcSEcCtD
Clofarabine—POLA1—Mitotic G1-G1/S phases—CCND1—urinary bladder cancer	2.29e-05	0.000738	CbGpPWpGaD
Clofarabine—Asthenia—Gemcitabine—urinary bladder cancer	2.28e-05	0.000566	CcSEcCtD
Clofarabine—RRM1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	2.28e-05	0.000736	CbGpPWpGaD
Clofarabine—Haematuria—Epirubicin—urinary bladder cancer	2.28e-05	0.000564	CcSEcCtD
Clofarabine—RRM1—Metabolism—NAT2—urinary bladder cancer	2.28e-05	0.000734	CbGpPWpGaD
Clofarabine—Urinary tract disorder—Methotrexate—urinary bladder cancer	2.26e-05	0.000561	CcSEcCtD
Clofarabine—Hepatobiliary disease—Epirubicin—urinary bladder cancer	2.26e-05	0.00056	CcSEcCtD
Clofarabine—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—urinary bladder cancer	2.26e-05	0.000729	CbGpPWpGaD
Clofarabine—Epistaxis—Epirubicin—urinary bladder cancer	2.25e-05	0.000558	CcSEcCtD
Clofarabine—Pruritus—Gemcitabine—urinary bladder cancer	2.25e-05	0.000558	CcSEcCtD
Clofarabine—Nausea—Thiotepa—urinary bladder cancer	2.25e-05	0.000557	CcSEcCtD
Clofarabine—Urethral disorder—Methotrexate—urinary bladder cancer	2.25e-05	0.000556	CcSEcCtD
Clofarabine—Weight decreased—Doxorubicin—urinary bladder cancer	2.24e-05	0.000556	CcSEcCtD
Clofarabine—Sinusitis—Epirubicin—urinary bladder cancer	2.24e-05	0.000555	CcSEcCtD
Clofarabine—Feeling abnormal—Etoposide—urinary bladder cancer	2.24e-05	0.000555	CcSEcCtD
Clofarabine—Pneumonia—Doxorubicin—urinary bladder cancer	2.22e-05	0.000551	CcSEcCtD
Clofarabine—Gastrointestinal pain—Etoposide—urinary bladder cancer	2.22e-05	0.000551	CcSEcCtD
Clofarabine—RRM2—Cell Cycle—CCNE1—urinary bladder cancer	2.22e-05	0.000716	CbGpPWpGaD
Clofarabine—POLA1—Mitotic G1-G1/S phases—CDKN1A—urinary bladder cancer	2.22e-05	0.000714	CbGpPWpGaD
Clofarabine—Pruritus—Fluorouracil—urinary bladder cancer	2.22e-05	0.000548	CcSEcCtD
Clofarabine—Infestation NOS—Doxorubicin—urinary bladder cancer	2.21e-05	0.000548	CcSEcCtD
Clofarabine—Infestation—Doxorubicin—urinary bladder cancer	2.21e-05	0.000548	CcSEcCtD
Clofarabine—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	2.19e-05	0.000543	CcSEcCtD
Clofarabine—POLA1—Cell Cycle—SMC1A—urinary bladder cancer	2.19e-05	0.000706	CbGpPWpGaD
Clofarabine—Hypersensitivity—Cisplatin—urinary bladder cancer	2.19e-05	0.000541	CcSEcCtD
Clofarabine—RRM2—Cell Cycle—TYMS—urinary bladder cancer	2.18e-05	0.000703	CbGpPWpGaD
Clofarabine—POLA1—G1/S Transition—MYC—urinary bladder cancer	2.18e-05	0.000703	CbGpPWpGaD
Clofarabine—Diarrhoea—Gemcitabine—urinary bladder cancer	2.18e-05	0.000539	CcSEcCtD
Clofarabine—Renal failure—Doxorubicin—urinary bladder cancer	2.17e-05	0.000538	CcSEcCtD
Clofarabine—Erythema multiforme—Methotrexate—urinary bladder cancer	2.17e-05	0.000537	CcSEcCtD
Clofarabine—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	2.17e-05	0.000537	CcSEcCtD
Clofarabine—Haemoglobin—Epirubicin—urinary bladder cancer	2.16e-05	0.000534	CcSEcCtD
Clofarabine—Stomatitis—Doxorubicin—urinary bladder cancer	2.16e-05	0.000534	CcSEcCtD
Clofarabine—Jaundice—Doxorubicin—urinary bladder cancer	2.16e-05	0.000534	CcSEcCtD
Clofarabine—Body temperature increased—Etoposide—urinary bladder cancer	2.15e-05	0.000532	CcSEcCtD
Clofarabine—Abdominal pain—Etoposide—urinary bladder cancer	2.15e-05	0.000532	CcSEcCtD
Clofarabine—Haemorrhage—Epirubicin—urinary bladder cancer	2.15e-05	0.000531	CcSEcCtD
Clofarabine—POLA1—Retinoblastoma (RB) in Cancer—TP53—urinary bladder cancer	2.14e-05	0.000691	CbGpPWpGaD
Clofarabine—Diarrhoea—Fluorouracil—urinary bladder cancer	2.14e-05	0.00053	CcSEcCtD
Clofarabine—Asthenia—Cisplatin—urinary bladder cancer	2.13e-05	0.000527	CcSEcCtD
Clofarabine—Cardiac disorder—Methotrexate—urinary bladder cancer	2.13e-05	0.000527	CcSEcCtD
Clofarabine—Urinary tract disorder—Epirubicin—urinary bladder cancer	2.12e-05	0.000525	CcSEcCtD
Clofarabine—Oedema peripheral—Epirubicin—urinary bladder cancer	2.11e-05	0.000523	CcSEcCtD
Clofarabine—Haematuria—Doxorubicin—urinary bladder cancer	2.11e-05	0.000522	CcSEcCtD
Clofarabine—Connective tissue disorder—Epirubicin—urinary bladder cancer	2.11e-05	0.000522	CcSEcCtD
Clofarabine—Urethral disorder—Epirubicin—urinary bladder cancer	2.1e-05	0.000521	CcSEcCtD
Clofarabine—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	2.09e-05	0.000518	CcSEcCtD
Clofarabine—Epistaxis—Doxorubicin—urinary bladder cancer	2.09e-05	0.000516	CcSEcCtD
Clofarabine—Angiopathy—Methotrexate—urinary bladder cancer	2.08e-05	0.000515	CcSEcCtD
Clofarabine—Sinusitis—Doxorubicin—urinary bladder cancer	2.07e-05	0.000514	CcSEcCtD
Clofarabine—RRM2—Metabolism—TYMP—urinary bladder cancer	2.07e-05	0.000669	CbGpPWpGaD
Clofarabine—Immune system disorder—Methotrexate—urinary bladder cancer	2.07e-05	0.000513	CcSEcCtD
Clofarabine—Dizziness—Fluorouracil—urinary bladder cancer	2.07e-05	0.000513	CcSEcCtD
Clofarabine—Mediastinal disorder—Methotrexate—urinary bladder cancer	2.07e-05	0.000512	CcSEcCtD
Clofarabine—Chills—Methotrexate—urinary bladder cancer	2.06e-05	0.000509	CcSEcCtD
Clofarabine—ABCG2—HIF-1-alpha transcription factor network—EP300—urinary bladder cancer	2.04e-05	0.000659	CbGpPWpGaD
Clofarabine—Diarrhoea—Cisplatin—urinary bladder cancer	2.03e-05	0.000503	CcSEcCtD
Clofarabine—RRM1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	2.03e-05	0.000654	CbGpPWpGaD
Clofarabine—Erythema multiforme—Epirubicin—urinary bladder cancer	2.03e-05	0.000502	CcSEcCtD
Clofarabine—Alopecia—Methotrexate—urinary bladder cancer	2.03e-05	0.000502	CcSEcCtD
Clofarabine—Vomiting—Gemcitabine—urinary bladder cancer	2.02e-05	0.000501	CcSEcCtD
Clofarabine—Mental disorder—Methotrexate—urinary bladder cancer	2.01e-05	0.000497	CcSEcCtD
Clofarabine—Rash—Gemcitabine—urinary bladder cancer	2.01e-05	0.000497	CcSEcCtD
Clofarabine—Dermatitis—Gemcitabine—urinary bladder cancer	2.01e-05	0.000497	CcSEcCtD
Clofarabine—Hypersensitivity—Etoposide—urinary bladder cancer	2e-05	0.000496	CcSEcCtD
Clofarabine—Erythema—Methotrexate—urinary bladder cancer	2e-05	0.000494	CcSEcCtD
Clofarabine—Malnutrition—Methotrexate—urinary bladder cancer	2e-05	0.000494	CcSEcCtD
Clofarabine—Haemoglobin—Doxorubicin—urinary bladder cancer	2e-05	0.000494	CcSEcCtD
Clofarabine—Headache—Gemcitabine—urinary bladder cancer	1.99e-05	0.000494	CcSEcCtD
Clofarabine—Flushing—Epirubicin—urinary bladder cancer	1.99e-05	0.000493	CcSEcCtD
Clofarabine—Cardiac disorder—Epirubicin—urinary bladder cancer	1.99e-05	0.000493	CcSEcCtD
Clofarabine—Vomiting—Fluorouracil—urinary bladder cancer	1.99e-05	0.000493	CcSEcCtD
Clofarabine—Haemorrhage—Doxorubicin—urinary bladder cancer	1.99e-05	0.000492	CcSEcCtD
Clofarabine—POLA1—S Phase—MYC—urinary bladder cancer	1.98e-05	0.000638	CbGpPWpGaD
Clofarabine—ABCG2—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	1.98e-05	0.000637	CbGpPWpGaD
Clofarabine—Rash—Fluorouracil—urinary bladder cancer	1.97e-05	0.000489	CcSEcCtD
Clofarabine—Dermatitis—Fluorouracil—urinary bladder cancer	1.97e-05	0.000488	CcSEcCtD
Clofarabine—RRM1—Metabolism—RRM2—urinary bladder cancer	1.97e-05	0.000634	CbGpPWpGaD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	1.96e-05	0.000633	CbGpPWpGaD
Clofarabine—Headache—Fluorouracil—urinary bladder cancer	1.96e-05	0.000486	CcSEcCtD
Clofarabine—Urinary tract disorder—Doxorubicin—urinary bladder cancer	1.96e-05	0.000485	CcSEcCtD
Clofarabine—Oedema peripheral—Doxorubicin—urinary bladder cancer	1.96e-05	0.000484	CcSEcCtD
Clofarabine—Asthenia—Etoposide—urinary bladder cancer	1.95e-05	0.000483	CcSEcCtD
Clofarabine—Connective tissue disorder—Doxorubicin—urinary bladder cancer	1.95e-05	0.000483	CcSEcCtD
Clofarabine—Angiopathy—Epirubicin—urinary bladder cancer	1.95e-05	0.000482	CcSEcCtD
Clofarabine—Urethral disorder—Doxorubicin—urinary bladder cancer	1.95e-05	0.000482	CcSEcCtD
Clofarabine—Immune system disorder—Epirubicin—urinary bladder cancer	1.94e-05	0.00048	CcSEcCtD
Clofarabine—DCK—Metabolism—TYMP—urinary bladder cancer	1.94e-05	0.000625	CbGpPWpGaD
Clofarabine—Mediastinal disorder—Epirubicin—urinary bladder cancer	1.93e-05	0.000479	CcSEcCtD
Clofarabine—Back pain—Methotrexate—urinary bladder cancer	1.93e-05	0.000478	CcSEcCtD
Clofarabine—Chills—Epirubicin—urinary bladder cancer	1.92e-05	0.000477	CcSEcCtD
Clofarabine—Pruritus—Etoposide—urinary bladder cancer	1.92e-05	0.000476	CcSEcCtD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	1.92e-05	0.000619	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle, Mitotic—CDK4—urinary bladder cancer	1.9e-05	0.000613	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle—TERT—urinary bladder cancer	1.9e-05	0.000613	CbGpPWpGaD
Clofarabine—Alopecia—Epirubicin—urinary bladder cancer	1.9e-05	0.000469	CcSEcCtD
Clofarabine—Nausea—Gemcitabine—urinary bladder cancer	1.89e-05	0.000468	CcSEcCtD
Clofarabine—Vomiting—Cisplatin—urinary bladder cancer	1.89e-05	0.000467	CcSEcCtD
Clofarabine—Mental disorder—Epirubicin—urinary bladder cancer	1.88e-05	0.000465	CcSEcCtD
Clofarabine—Erythema multiforme—Doxorubicin—urinary bladder cancer	1.88e-05	0.000465	CcSEcCtD
Clofarabine—RRM2—Metabolism—NAT2—urinary bladder cancer	1.87e-05	0.000605	CbGpPWpGaD
Clofarabine—Rash—Cisplatin—urinary bladder cancer	1.87e-05	0.000463	CcSEcCtD
Clofarabine—Dermatitis—Cisplatin—urinary bladder cancer	1.87e-05	0.000463	CcSEcCtD
Clofarabine—Erythema—Epirubicin—urinary bladder cancer	1.87e-05	0.000462	CcSEcCtD
Clofarabine—Malnutrition—Epirubicin—urinary bladder cancer	1.87e-05	0.000462	CcSEcCtD
Clofarabine—Diarrhoea—Etoposide—urinary bladder cancer	1.86e-05	0.000461	CcSEcCtD
Clofarabine—Nausea—Fluorouracil—urinary bladder cancer	1.86e-05	0.00046	CcSEcCtD
Clofarabine—Anaemia—Methotrexate—urinary bladder cancer	1.84e-05	0.000457	CcSEcCtD
Clofarabine—Flushing—Doxorubicin—urinary bladder cancer	1.84e-05	0.000456	CcSEcCtD
Clofarabine—Cardiac disorder—Doxorubicin—urinary bladder cancer	1.84e-05	0.000456	CcSEcCtD
Clofarabine—POLA1—Mitotic G1-G1/S phases—MYC—urinary bladder cancer	1.84e-05	0.000592	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—HPGDS—urinary bladder cancer	1.82e-05	0.000587	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—ENO2—urinary bladder cancer	1.82e-05	0.000587	CbGpPWpGaD
Clofarabine—Back pain—Epirubicin—urinary bladder cancer	1.81e-05	0.000447	CcSEcCtD
Clofarabine—Angiopathy—Doxorubicin—urinary bladder cancer	1.8e-05	0.000446	CcSEcCtD
Clofarabine—Dizziness—Etoposide—urinary bladder cancer	1.8e-05	0.000445	CcSEcCtD
Clofarabine—Immune system disorder—Doxorubicin—urinary bladder cancer	1.79e-05	0.000444	CcSEcCtD
Clofarabine—Mediastinal disorder—Doxorubicin—urinary bladder cancer	1.79e-05	0.000443	CcSEcCtD
Clofarabine—Leukopenia—Methotrexate—urinary bladder cancer	1.79e-05	0.000442	CcSEcCtD
Clofarabine—Chills—Doxorubicin—urinary bladder cancer	1.78e-05	0.000441	CcSEcCtD
Clofarabine—RRM1—Metabolism—GSTT1—urinary bladder cancer	1.77e-05	0.000569	CbGpPWpGaD
Clofarabine—Nausea—Cisplatin—urinary bladder cancer	1.76e-05	0.000437	CcSEcCtD
Clofarabine—Alopecia—Doxorubicin—urinary bladder cancer	1.75e-05	0.000434	CcSEcCtD
Clofarabine—DCK—Metabolism—NAT2—urinary bladder cancer	1.75e-05	0.000565	CbGpPWpGaD
Clofarabine—Cough—Methotrexate—urinary bladder cancer	1.74e-05	0.000431	CcSEcCtD
Clofarabine—Mental disorder—Doxorubicin—urinary bladder cancer	1.74e-05	0.000431	CcSEcCtD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	1.73e-05	0.000559	CbGpPWpGaD
Clofarabine—Vomiting—Etoposide—urinary bladder cancer	1.73e-05	0.000428	CcSEcCtD
Clofarabine—Erythema—Doxorubicin—urinary bladder cancer	1.73e-05	0.000428	CcSEcCtD
Clofarabine—Malnutrition—Doxorubicin—urinary bladder cancer	1.73e-05	0.000428	CcSEcCtD
Clofarabine—Anaemia—Epirubicin—urinary bladder cancer	1.73e-05	0.000427	CcSEcCtD
Clofarabine—Agitation—Epirubicin—urinary bladder cancer	1.72e-05	0.000425	CcSEcCtD
Clofarabine—Rash—Etoposide—urinary bladder cancer	1.71e-05	0.000425	CcSEcCtD
Clofarabine—Dermatitis—Etoposide—urinary bladder cancer	1.71e-05	0.000424	CcSEcCtD
Clofarabine—RRM2—Cell Cycle—ATM—urinary bladder cancer	1.71e-05	0.000551	CbGpPWpGaD
Clofarabine—Headache—Etoposide—urinary bladder cancer	1.7e-05	0.000422	CcSEcCtD
Clofarabine—RRM2—Cell Cycle—CDK4—urinary bladder cancer	1.7e-05	0.000548	CbGpPWpGaD
Clofarabine—Myalgia—Methotrexate—urinary bladder cancer	1.7e-05	0.000421	CcSEcCtD
Clofarabine—Arthralgia—Methotrexate—urinary bladder cancer	1.7e-05	0.000421	CcSEcCtD
Clofarabine—POLA1—Cell Cycle, Mitotic—CCNE1—urinary bladder cancer	1.7e-05	0.000548	CbGpPWpGaD
Clofarabine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	1.69e-05	0.000418	CcSEcCtD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	1.68e-05	0.000541	CbGpPWpGaD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	1.67e-05	0.00054	CbGpPWpGaD
Clofarabine—Leukopenia—Epirubicin—urinary bladder cancer	1.67e-05	0.000414	CcSEcCtD
Clofarabine—Back pain—Doxorubicin—urinary bladder cancer	1.67e-05	0.000414	CcSEcCtD
Clofarabine—POLA1—Cell Cycle, Mitotic—TYMS—urinary bladder cancer	1.67e-05	0.000538	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle, Mitotic—RB1—urinary bladder cancer	1.65e-05	0.000533	CbGpPWpGaD
Clofarabine—Cough—Epirubicin—urinary bladder cancer	1.63e-05	0.000404	CcSEcCtD
Clofarabine—Infection—Methotrexate—urinary bladder cancer	1.62e-05	0.000401	CcSEcCtD
Clofarabine—Nausea—Etoposide—urinary bladder cancer	1.62e-05	0.0004	CcSEcCtD
Clofarabine—Hypertension—Epirubicin—urinary bladder cancer	1.61e-05	0.000399	CcSEcCtD
Clofarabine—ABCG2—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	1.61e-05	0.000519	CbGpPWpGaD
Clofarabine—Nervous system disorder—Methotrexate—urinary bladder cancer	1.6e-05	0.000395	CcSEcCtD
Clofarabine—Anaemia—Doxorubicin—urinary bladder cancer	1.6e-05	0.000395	CcSEcCtD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	1.6e-05	0.000515	CbGpPWpGaD
Clofarabine—Thrombocytopenia—Methotrexate—urinary bladder cancer	1.59e-05	0.000395	CcSEcCtD
Clofarabine—Myalgia—Epirubicin—urinary bladder cancer	1.59e-05	0.000394	CcSEcCtD
Clofarabine—Arthralgia—Epirubicin—urinary bladder cancer	1.59e-05	0.000394	CcSEcCtD
Clofarabine—Agitation—Doxorubicin—urinary bladder cancer	1.59e-05	0.000393	CcSEcCtD
Clofarabine—Anxiety—Epirubicin—urinary bladder cancer	1.58e-05	0.000392	CcSEcCtD
Clofarabine—Skin disorder—Methotrexate—urinary bladder cancer	1.58e-05	0.000392	CcSEcCtD
Clofarabine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	1.58e-05	0.000391	CcSEcCtD
Clofarabine—Hyperhidrosis—Methotrexate—urinary bladder cancer	1.57e-05	0.00039	CcSEcCtD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	1.55e-05	0.000501	CbGpPWpGaD
Clofarabine—Anorexia—Methotrexate—urinary bladder cancer	1.55e-05	0.000384	CcSEcCtD
Clofarabine—Leukopenia—Doxorubicin—urinary bladder cancer	1.55e-05	0.000383	CcSEcCtD
Clofarabine—Oedema—Epirubicin—urinary bladder cancer	1.52e-05	0.000377	CcSEcCtD
Clofarabine—Hypotension—Methotrexate—urinary bladder cancer	1.52e-05	0.000377	CcSEcCtD
Clofarabine—POLA1—Cell Cycle—CCNE1—urinary bladder cancer	1.52e-05	0.00049	CbGpPWpGaD
Clofarabine—Infection—Epirubicin—urinary bladder cancer	1.51e-05	0.000375	CcSEcCtD
Clofarabine—DCK—Metabolism—RRM2—urinary bladder cancer	1.51e-05	0.000488	CbGpPWpGaD
Clofarabine—POLA1—Mitotic M-M/G1 phases—RB1—urinary bladder cancer	1.51e-05	0.000488	CbGpPWpGaD
Clofarabine—Cough—Doxorubicin—urinary bladder cancer	1.51e-05	0.000373	CcSEcCtD
Clofarabine—RRM2—Metabolism—HPGDS—urinary bladder cancer	1.5e-05	0.000483	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—ENO2—urinary bladder cancer	1.5e-05	0.000483	CbGpPWpGaD
Clofarabine—Nervous system disorder—Epirubicin—urinary bladder cancer	1.49e-05	0.00037	CcSEcCtD
Clofarabine—Thrombocytopenia—Epirubicin—urinary bladder cancer	1.49e-05	0.00037	CcSEcCtD
Clofarabine—Hypertension—Doxorubicin—urinary bladder cancer	1.49e-05	0.000369	CcSEcCtD
Clofarabine—POLA1—Cell Cycle—TYMS—urinary bladder cancer	1.49e-05	0.000481	CbGpPWpGaD
Clofarabine—Tachycardia—Epirubicin—urinary bladder cancer	1.49e-05	0.000368	CcSEcCtD
Clofarabine—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	1.48e-05	0.000367	CcSEcCtD
Clofarabine—Skin disorder—Epirubicin—urinary bladder cancer	1.48e-05	0.000367	CcSEcCtD
Clofarabine—RRM2—Cell Cycle—RB1—urinary bladder cancer	1.48e-05	0.000477	CbGpPWpGaD
Clofarabine—Hyperhidrosis—Epirubicin—urinary bladder cancer	1.47e-05	0.000365	CcSEcCtD
Clofarabine—Myalgia—Doxorubicin—urinary bladder cancer	1.47e-05	0.000364	CcSEcCtD
Clofarabine—Arthralgia—Doxorubicin—urinary bladder cancer	1.47e-05	0.000364	CcSEcCtD
Clofarabine—RRM1—Metabolism—NQO1—urinary bladder cancer	1.47e-05	0.000473	CbGpPWpGaD
Clofarabine—Anxiety—Doxorubicin—urinary bladder cancer	1.47e-05	0.000363	CcSEcCtD
Clofarabine—Paraesthesia—Methotrexate—urinary bladder cancer	1.46e-05	0.000362	CcSEcCtD
Clofarabine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	1.46e-05	0.000362	CcSEcCtD
Clofarabine—RRM2—Metabolism—GSTT1—urinary bladder cancer	1.45e-05	0.000469	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle, Mitotic—CDKN2A—urinary bladder cancer	1.45e-05	0.000469	CbGpPWpGaD
Clofarabine—Anorexia—Epirubicin—urinary bladder cancer	1.45e-05	0.00036	CcSEcCtD
Clofarabine—Dyspnoea—Methotrexate—urinary bladder cancer	1.45e-05	0.00036	CcSEcCtD
Clofarabine—Somnolence—Methotrexate—urinary bladder cancer	1.45e-05	0.000359	CcSEcCtD
Clofarabine—Hypotension—Epirubicin—urinary bladder cancer	1.42e-05	0.000353	CcSEcCtD
Clofarabine—Decreased appetite—Methotrexate—urinary bladder cancer	1.42e-05	0.000351	CcSEcCtD
Clofarabine—Oedema—Doxorubicin—urinary bladder cancer	1.41e-05	0.000349	CcSEcCtD
Clofarabine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	1.41e-05	0.000348	CcSEcCtD
Clofarabine—Fatigue—Methotrexate—urinary bladder cancer	1.4e-05	0.000348	CcSEcCtD
Clofarabine—Infection—Doxorubicin—urinary bladder cancer	1.4e-05	0.000347	CcSEcCtD
Clofarabine—DCK—Metabolism—HPGDS—urinary bladder cancer	1.4e-05	0.000452	CbGpPWpGaD
Clofarabine—DCK—Metabolism—ENO2—urinary bladder cancer	1.4e-05	0.000452	CbGpPWpGaD
Clofarabine—Pain—Methotrexate—urinary bladder cancer	1.39e-05	0.000345	CcSEcCtD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	1.39e-05	0.000449	CbGpPWpGaD
Clofarabine—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	1.39e-05	0.000344	CcSEcCtD
Clofarabine—Nervous system disorder—Doxorubicin—urinary bladder cancer	1.38e-05	0.000342	CcSEcCtD
Clofarabine—Thrombocytopenia—Doxorubicin—urinary bladder cancer	1.38e-05	0.000342	CcSEcCtD
Clofarabine—Tachycardia—Doxorubicin—urinary bladder cancer	1.38e-05	0.000341	CcSEcCtD
Clofarabine—Skin disorder—Doxorubicin—urinary bladder cancer	1.37e-05	0.000339	CcSEcCtD
Clofarabine—Paraesthesia—Epirubicin—urinary bladder cancer	1.37e-05	0.000339	CcSEcCtD
Clofarabine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	1.36e-05	0.000338	CcSEcCtD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	1.36e-05	0.000439	CbGpPWpGaD
Clofarabine—Dyspnoea—Epirubicin—urinary bladder cancer	1.36e-05	0.000336	CcSEcCtD
Clofarabine—DCK—Metabolism—GSTT1—urinary bladder cancer	1.36e-05	0.000438	CbGpPWpGaD
Clofarabine—Somnolence—Epirubicin—urinary bladder cancer	1.35e-05	0.000336	CcSEcCtD
Clofarabine—ABCG2—Metabolism—GSTZ1—urinary bladder cancer	1.35e-05	0.000435	CbGpPWpGaD
Clofarabine—Anorexia—Doxorubicin—urinary bladder cancer	1.34e-05	0.000333	CcSEcCtD
Clofarabine—Feeling abnormal—Methotrexate—urinary bladder cancer	1.34e-05	0.000332	CcSEcCtD
Clofarabine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	1.33e-05	0.00033	CcSEcCtD
Clofarabine—Decreased appetite—Epirubicin—urinary bladder cancer	1.32e-05	0.000328	CcSEcCtD
Clofarabine—Hypotension—Doxorubicin—urinary bladder cancer	1.32e-05	0.000326	CcSEcCtD
Clofarabine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	1.32e-05	0.000326	CcSEcCtD
Clofarabine—Fatigue—Epirubicin—urinary bladder cancer	1.31e-05	0.000325	CcSEcCtD
Clofarabine—Pain—Epirubicin—urinary bladder cancer	1.3e-05	0.000323	CcSEcCtD
Clofarabine—POLA1—Cell Cycle, Mitotic—CDK4—urinary bladder cancer	1.3e-05	0.000419	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle—CDKN2A—urinary bladder cancer	1.3e-05	0.000419	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle—TERT—urinary bladder cancer	1.3e-05	0.000419	CbGpPWpGaD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	1.3e-05	0.000418	CbGpPWpGaD
Clofarabine—Body temperature increased—Methotrexate—urinary bladder cancer	1.29e-05	0.000319	CcSEcCtD
Clofarabine—Abdominal pain—Methotrexate—urinary bladder cancer	1.29e-05	0.000319	CcSEcCtD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	1.29e-05	0.000415	CbGpPWpGaD
Clofarabine—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	1.28e-05	0.000318	CcSEcCtD
Clofarabine—ABCG2—Metabolism—GSTO2—urinary bladder cancer	1.28e-05	0.000413	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—NAT1—urinary bladder cancer	1.28e-05	0.000413	CbGpPWpGaD
Clofarabine—Paraesthesia—Doxorubicin—urinary bladder cancer	1.27e-05	0.000314	CcSEcCtD
Clofarabine—Dyspnoea—Doxorubicin—urinary bladder cancer	1.26e-05	0.000311	CcSEcCtD
Clofarabine—Feeling abnormal—Epirubicin—urinary bladder cancer	1.26e-05	0.000311	CcSEcCtD
Clofarabine—Somnolence—Doxorubicin—urinary bladder cancer	1.25e-05	0.00031	CcSEcCtD
Clofarabine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	1.25e-05	0.000309	CcSEcCtD
Clofarabine—RRM2—Cell Cycle, Mitotic—CCND1—urinary bladder cancer	1.23e-05	0.000396	CbGpPWpGaD
Clofarabine—Decreased appetite—Doxorubicin—urinary bladder cancer	1.23e-05	0.000304	CcSEcCtD
Clofarabine—RRM1—Metabolism—GSTP1—urinary bladder cancer	1.22e-05	0.000395	CbGpPWpGaD
Clofarabine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	1.22e-05	0.000301	CcSEcCtD
Clofarabine—Fatigue—Doxorubicin—urinary bladder cancer	1.22e-05	0.000301	CcSEcCtD
Clofarabine—RRM2—Metabolism—NQO1—urinary bladder cancer	1.21e-05	0.00039	CbGpPWpGaD
Clofarabine—Pain—Doxorubicin—urinary bladder cancer	1.21e-05	0.000299	CcSEcCtD
Clofarabine—Body temperature increased—Epirubicin—urinary bladder cancer	1.2e-05	0.000298	CcSEcCtD
Clofarabine—Abdominal pain—Epirubicin—urinary bladder cancer	1.2e-05	0.000298	CcSEcCtD
Clofarabine—Hypersensitivity—Methotrexate—urinary bladder cancer	1.2e-05	0.000297	CcSEcCtD
Clofarabine—RRM2—Cell Cycle, Mitotic—CDKN1A—urinary bladder cancer	1.19e-05	0.000383	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—UGT2B7—urinary bladder cancer	1.17e-05	0.000377	CbGpPWpGaD
Clofarabine—Asthenia—Methotrexate—urinary bladder cancer	1.17e-05	0.000289	CcSEcCtD
Clofarabine—POLA1—Cell Cycle—ATM—urinary bladder cancer	1.17e-05	0.000377	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle—CDK4—urinary bladder cancer	1.16e-05	0.000375	CbGpPWpGaD
Clofarabine—Feeling abnormal—Doxorubicin—urinary bladder cancer	1.16e-05	0.000288	CcSEcCtD
Clofarabine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	1.15e-05	0.000286	CcSEcCtD
Clofarabine—Pruritus—Methotrexate—urinary bladder cancer	1.15e-05	0.000285	CcSEcCtD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.14e-05	0.000369	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—TYMS—urinary bladder cancer	1.14e-05	0.000367	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle, Mitotic—RB1—urinary bladder cancer	1.13e-05	0.000365	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle, Mitotic—EP300—urinary bladder cancer	1.13e-05	0.000364	CbGpPWpGaD
Clofarabine—DCK—Metabolism—NQO1—urinary bladder cancer	1.13e-05	0.000364	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—NCOR1—urinary bladder cancer	1.12e-05	0.000363	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—GSTM1—urinary bladder cancer	1.12e-05	0.000363	CbGpPWpGaD
Clofarabine—Hypersensitivity—Epirubicin—urinary bladder cancer	1.12e-05	0.000278	CcSEcCtD
Clofarabine—Body temperature increased—Doxorubicin—urinary bladder cancer	1.11e-05	0.000276	CcSEcCtD
Clofarabine—Abdominal pain—Doxorubicin—urinary bladder cancer	1.11e-05	0.000276	CcSEcCtD
Clofarabine—Diarrhoea—Methotrexate—urinary bladder cancer	1.11e-05	0.000276	CcSEcCtD
Clofarabine—RRM2—Cell Cycle—CCND1—urinary bladder cancer	1.1e-05	0.000354	CbGpPWpGaD
Clofarabine—Asthenia—Epirubicin—urinary bladder cancer	1.09e-05	0.000271	CcSEcCtD
Clofarabine—ABCG2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	1.09e-05	0.000351	CbGpPWpGaD
Clofarabine—Pruritus—Epirubicin—urinary bladder cancer	1.08e-05	0.000267	CcSEcCtD
Clofarabine—Dizziness—Methotrexate—urinary bladder cancer	1.08e-05	0.000267	CcSEcCtD
Clofarabine—RRM1—Metabolism—GPX1—urinary bladder cancer	1.08e-05	0.000347	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle—CDKN1A—urinary bladder cancer	1.06e-05	0.000342	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—ERCC2—urinary bladder cancer	1.06e-05	0.000341	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—CYP4B1—urinary bladder cancer	1.05e-05	0.00034	CbGpPWpGaD
Clofarabine—Diarrhoea—Epirubicin—urinary bladder cancer	1.04e-05	0.000258	CcSEcCtD
Clofarabine—Hypersensitivity—Doxorubicin—urinary bladder cancer	1.04e-05	0.000257	CcSEcCtD
Clofarabine—Vomiting—Methotrexate—urinary bladder cancer	1.04e-05	0.000256	CcSEcCtD
Clofarabine—Rash—Methotrexate—urinary bladder cancer	1.03e-05	0.000254	CcSEcCtD
Clofarabine—Dermatitis—Methotrexate—urinary bladder cancer	1.03e-05	0.000254	CcSEcCtD
Clofarabine—Headache—Methotrexate—urinary bladder cancer	1.02e-05	0.000253	CcSEcCtD
Clofarabine—Asthenia—Doxorubicin—urinary bladder cancer	1.01e-05	0.000251	CcSEcCtD
Clofarabine—POLA1—Cell Cycle—RB1—urinary bladder cancer	1.01e-05	0.000326	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle—EP300—urinary bladder cancer	1.01e-05	0.000326	CbGpPWpGaD
Clofarabine—Dizziness—Epirubicin—urinary bladder cancer	1.01e-05	0.00025	CcSEcCtD
Clofarabine—RRM2—Metabolism—GSTP1—urinary bladder cancer	1.01e-05	0.000325	CbGpPWpGaD
Clofarabine—Pruritus—Doxorubicin—urinary bladder cancer	9.98e-06	0.000247	CcSEcCtD
Clofarabine—ABCG2—Metabolism—SLC19A1—urinary bladder cancer	9.95e-06	0.000321	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle, Mitotic—CDKN2A—urinary bladder cancer	9.94e-06	0.000321	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—MTHFR—urinary bladder cancer	9.94e-06	0.00032	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle, Mitotic—MYC—urinary bladder cancer	9.85e-06	0.000318	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—PRSS3—urinary bladder cancer	9.7e-06	0.000313	CbGpPWpGaD
Clofarabine—Vomiting—Epirubicin—urinary bladder cancer	9.69e-06	0.00024	CcSEcCtD
Clofarabine—Nausea—Methotrexate—urinary bladder cancer	9.67e-06	0.00024	CcSEcCtD
Clofarabine—Diarrhoea—Doxorubicin—urinary bladder cancer	9.65e-06	0.000239	CcSEcCtD
Clofarabine—Rash—Epirubicin—urinary bladder cancer	9.61e-06	0.000238	CcSEcCtD
Clofarabine—Dermatitis—Epirubicin—urinary bladder cancer	9.6e-06	0.000238	CcSEcCtD
Clofarabine—Headache—Epirubicin—urinary bladder cancer	9.55e-06	0.000236	CcSEcCtD
Clofarabine—DCK—Metabolism—GSTP1—urinary bladder cancer	9.42e-06	0.000304	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—TYMS—urinary bladder cancer	9.37e-06	0.000302	CbGpPWpGaD
Clofarabine—Dizziness—Doxorubicin—urinary bladder cancer	9.33e-06	0.000231	CcSEcCtD
Clofarabine—RRM2—Metabolism—GSTM1—urinary bladder cancer	9.26e-06	0.000299	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—NCOR1—urinary bladder cancer	9.26e-06	0.000299	CbGpPWpGaD
Clofarabine—Nausea—Epirubicin—urinary bladder cancer	9.05e-06	0.000224	CcSEcCtD
Clofarabine—Vomiting—Doxorubicin—urinary bladder cancer	8.97e-06	0.000222	CcSEcCtD
Clofarabine—Rash—Doxorubicin—urinary bladder cancer	8.89e-06	0.00022	CcSEcCtD
Clofarabine—POLA1—Cell Cycle—CDKN2A—urinary bladder cancer	8.89e-06	0.000287	CbGpPWpGaD
Clofarabine—Dermatitis—Doxorubicin—urinary bladder cancer	8.88e-06	0.00022	CcSEcCtD
Clofarabine—RRM2—Metabolism—GPX1—urinary bladder cancer	8.87e-06	0.000286	CbGpPWpGaD
Clofarabine—Headache—Doxorubicin—urinary bladder cancer	8.83e-06	0.000219	CcSEcCtD
Clofarabine—RRM2—Cell Cycle—MYC—urinary bladder cancer	8.81e-06	0.000284	CbGpPWpGaD
Clofarabine—DCK—Metabolism—TYMS—urinary bladder cancer	8.75e-06	0.000282	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—ERCC2—urinary bladder cancer	8.71e-06	0.000281	CbGpPWpGaD
Clofarabine—DCK—Metabolism—NCOR1—urinary bladder cancer	8.65e-06	0.000279	CbGpPWpGaD
Clofarabine—DCK—Metabolism—GSTM1—urinary bladder cancer	8.65e-06	0.000279	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle, Mitotic—CCND1—urinary bladder cancer	8.4e-06	0.000271	CbGpPWpGaD
Clofarabine—Nausea—Doxorubicin—urinary bladder cancer	8.38e-06	0.000207	CcSEcCtD
Clofarabine—DCK—Metabolism—GPX1—urinary bladder cancer	8.29e-06	0.000267	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—MTHFR—urinary bladder cancer	8.18e-06	0.000264	CbGpPWpGaD
Clofarabine—DCK—Metabolism—ERCC2—urinary bladder cancer	8.14e-06	0.000262	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle, Mitotic—CDKN1A—urinary bladder cancer	8.12e-06	0.000262	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—PPARG—urinary bladder cancer	8.06e-06	0.00026	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—TYMP—urinary bladder cancer	7.75e-06	0.00025	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—CREBBP—urinary bladder cancer	7.74e-06	0.00025	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle, Mitotic—EP300—urinary bladder cancer	7.73e-06	0.000249	CbGpPWpGaD
Clofarabine—DCK—Metabolism—MTHFR—urinary bladder cancer	7.65e-06	0.000247	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle—CCND1—urinary bladder cancer	7.51e-06	0.000242	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle—CDKN1A—urinary bladder cancer	7.26e-06	0.000234	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle—TP53—urinary bladder cancer	7.23e-06	0.000233	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—NAT2—urinary bladder cancer	7.01e-06	0.000226	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle—EP300—urinary bladder cancer	6.91e-06	0.000223	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle, Mitotic—MYC—urinary bladder cancer	6.74e-06	0.000217	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—PPARG—urinary bladder cancer	6.64e-06	0.000214	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—CREBBP—urinary bladder cancer	6.38e-06	0.000206	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—PTGS2—urinary bladder cancer	6.34e-06	0.000204	CbGpPWpGaD
Clofarabine—DCK—Metabolism—PPARG—urinary bladder cancer	6.2e-06	0.0002	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—RRM2—urinary bladder cancer	6.05e-06	0.000195	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle—MYC—urinary bladder cancer	6.02e-06	0.000194	CbGpPWpGaD
Clofarabine—DCK—Metabolism—CREBBP—urinary bladder cancer	5.96e-06	0.000192	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—ENO2—urinary bladder cancer	5.61e-06	0.000181	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—HPGDS—urinary bladder cancer	5.61e-06	0.000181	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—PTEN—urinary bladder cancer	5.53e-06	0.000178	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—GSTT1—urinary bladder cancer	5.44e-06	0.000175	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—EP300—urinary bladder cancer	5.27e-06	0.00017	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—PTGS2—urinary bladder cancer	5.22e-06	0.000168	CbGpPWpGaD
Clofarabine—ABCG2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	5.09e-06	0.000164	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle—TP53—urinary bladder cancer	4.95e-06	0.00016	CbGpPWpGaD
Clofarabine—DCK—Metabolism—PTGS2—urinary bladder cancer	4.88e-06	0.000157	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—PTEN—urinary bladder cancer	4.55e-06	0.000147	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—NQO1—urinary bladder cancer	4.52e-06	0.000146	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—EP300—urinary bladder cancer	4.34e-06	0.00014	CbGpPWpGaD
Clofarabine—DCK—Metabolism—PTEN—urinary bladder cancer	4.25e-06	0.000137	CbGpPWpGaD
Clofarabine—DCK—Metabolism—EP300—urinary bladder cancer	4.06e-06	0.000131	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—GSTP1—urinary bladder cancer	3.77e-06	0.000122	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—TYMS—urinary bladder cancer	3.5e-06	0.000113	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—NCOR1—urinary bladder cancer	3.46e-06	0.000112	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—GSTM1—urinary bladder cancer	3.46e-06	0.000112	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—GPX1—urinary bladder cancer	3.32e-06	0.000107	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—ERCC2—urinary bladder cancer	3.26e-06	0.000105	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—MTHFR—urinary bladder cancer	3.06e-06	9.87e-05	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—PPARG—urinary bladder cancer	2.48e-06	8e-05	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—CREBBP—urinary bladder cancer	2.38e-06	7.69e-05	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—PTGS2—urinary bladder cancer	1.95e-06	6.3e-05	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—PTEN—urinary bladder cancer	1.7e-06	5.49e-05	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—EP300—urinary bladder cancer	1.62e-06	5.24e-05	CbGpPWpGaD
